- Home
- MLAC vs TNGX Comparison
MLAC vs TNGX Comparison
Compare MLAC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLAC
- TNGX
- Stock Information
- Founded
- MLAC 2024
- TNGX 2014
- Country
- MLAC United States
- TNGX United States
- Employees
- MLAC N/A
- TNGX N/A
- Industry
- MLAC
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- MLAC
- TNGX Health Care
- Exchange
- MLAC NYSE
- TNGX Nasdaq
- Market Cap
- MLAC 311.7M
- TNGX 317.4M
- IPO Year
- MLAC 2024
- TNGX N/A
- Fundamental
- Price
- MLAC $10.06
- TNGX $1.28
- Analyst Decision
- MLAC
- TNGX Strong Buy
- Analyst Count
- MLAC 0
- TNGX 7
- Target Price
- MLAC N/A
- TNGX $12.33
- AVG Volume (30 Days)
- MLAC 45.3K
- TNGX 789.6K
- Earning Date
- MLAC 01-01-0001
- TNGX 05-07-2025
- Dividend Yield
- MLAC N/A
- TNGX N/A
- EPS Growth
- MLAC N/A
- TNGX N/A
- EPS
- MLAC N/A
- TNGX N/A
- Revenue
- MLAC N/A
- TNGX $42,069,000.00
- Revenue This Year
- MLAC N/A
- TNGX N/A
- Revenue Next Year
- MLAC N/A
- TNGX N/A
- P/E Ratio
- MLAC $410.28
- TNGX N/A
- Revenue Growth
- MLAC N/A
- TNGX 15.17
- 52 Week Low
- MLAC $9.94
- TNGX $1.24
- 52 Week High
- MLAC $10.17
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- MLAC N/A
- TNGX 24.31
- Support Level
- MLAC N/A
- TNGX $1.48
- Resistance Level
- MLAC N/A
- TNGX $1.66
- Average True Range (ATR)
- MLAC 0.00
- TNGX 0.16
- MACD
- MLAC 0.00
- TNGX -0.02
- Stochastic Oscillator
- MLAC 0.00
- TNGX 5.00
About MLAC MOUNTAIN LAKE ACQUISITION CORP
Mountain Lake Acquisition Corp is a blank check company.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.